New Antimicrobials for Gram-Positive Sustained Infections: A Comprehensive Guide for Clinicians.
Davide CarcioneJari IntraLilia AndrianiFloriana CampanileFloriana GonaSilvia CarlettiNicasio ManciniGioconda BriganteDario CattaneoSara BaldelliMattia ChisariAlessandra PiccirilliStefano di BellaLuigi PrincipePublished in: Pharmaceuticals (Basel, Switzerland) (2023)
Antibiotic resistance is a public health problem with increasingly alarming data being reported. Gram-positive bacteria are among the protagonists of severe nosocomial and community infections. The objective of this review is to conduct an extensive examination of emerging treatments for Gram-positive infections including ceftobiprole, ceftaroline, dalbavancin, oritavancin, omadacycline, tedizolid, and delafloxacin. From a methodological standpoint, a comprehensive analysis on clinical trials, molecular structure, mechanism of action, microbiological targeting, clinical use, pharmacokinetic/pharmacodynamic features, and potential for therapeutic drug monitoring will be addressed. Each antibiotic paragraph is divided into specialized microbiological, clinical, and pharmacological sections, including detailed and appropriate tables. A better understanding of the latest promising advances in the field of therapeutic options could lead to the development of a better approach in managing antimicrobial therapy for multidrug-resistant Gram-positive pathogens, which increasingly needs to be better stratified and targeted.
Keyphrases
- gram negative
- multidrug resistant
- public health
- acinetobacter baumannii
- clinical trial
- drug resistant
- klebsiella pneumoniae
- palliative care
- cancer therapy
- methicillin resistant staphylococcus aureus
- mental health
- staphylococcus aureus
- randomized controlled trial
- pseudomonas aeruginosa
- risk assessment
- open label
- climate change
- deep learning
- single molecule
- human health
- global health